====== Katrin Lamszus ======

===== Latest PubMed Articles =====

{{rss>https://pubmed.ncbi.nlm.nih.gov/rss/search/1la0KilYwPOMHxAnbzkLlsaiivEIn0dUmssQZpbf82UaUZXst1/?limit=15&utm_campaign=pubmed-2&fc=20250504112623}}

Prof. Dr. med. Katrin Lamszus is a distinguished neuroscientist specializing in [[brain tumor biology]]. She leads the Laboratory for Brain Tumor Biology within the Department of Neurosurgery at the University Medical Center Hamburg-Eppendorf (UKE) in Germany. Her research focuses on the molecular and cellular mechanisms underlying primary and metastatic brain tumors, particularly glioblastoma and brain metastases.

----
Prof. Lamszus's work encompasses areas such as glioma stem-like cells, tumor heterogeneity, and the tumor microenvironment. She has contributed to studies on epidermal growth factor receptor (EGFR) amplification in glioblastoma stem-like cells, exploring how EGFR status affects tumor behavior and therapeutic response. 

----
In addition to her research, Prof. Lamszus is involved in collaborative projects like the German Meningioma Consortium, where she investigates extracellular vesicles as biomarkers for meningioma subtypes and therapy response. 
german-meningioma-consortium.com

Her contributions to neuro-oncology are recognized through her role as an Associate Editor for journals such as Neuro-Oncology Advances. 
OUP Academic

For more information on Prof. Lamszus's work and publications, you can visit her profile on the University Medical Center Hamburg-Eppendorf [[https://www.uke.de/english/physicians-and-scientists/wissenschaftlerprofilseite_katrin_lamszus.html?utm_source=chatgpt.com|website]].
----
Mughal et al. performed [[transcriptome-wide gene expression profiling]] combined with [[spatial immune cell profiling]] to characterize the [[tumor immune microenvironment]] in 95 patients with BrM from different [[primary tumor]]s. 
They found that BrM from [[lung cancer]] and malignant [[melanoma]] showed overall higher [[immune cell infiltration]] as compared to BrM from [[breast cancer]]. [[RNA sequencing-based immune cell deconvolution]] revealed [[gene expression]] [[signature]]s indicative of [[tertiary lymphoid structure]]s (TLS) in subsets of BrM, mostly from lung cancer and melanoma. This finding was corroborated by [[multiplex immunofluorescence staining]] of [[immune cell]]s in BrM tissue sections. Detection of TLS signatures was more common in [[treatment]]-naïve BrM and associated with prolonged [[survival]] after [[Brain metastases diagnosis]] in [[lung cancer]] patients. 
The findings highlight the cellular [[diversity]] of the [[tumor immune microenvironment]] in BrM of different [[cancer]] types and suggest a role of TLS formation for BrM [[patient outcome]]
((Mughal SS, Reiss Y, Felsberg J, Meyer L, Macas J, Schlue S, Starzetz T, Köhrer K, Fehm T, Müller V, Lamszus K, Schadendorf D, Helfrich I, Wikman H, Berghoff A, Brors B, Plate KH, Reifenberger G. [[Identification]] and [[characterization]] of [[tertiary lymphoid structure]]s in [[brain metastases]]. Acta Neuropathol Commun. 2025 May 3;13(1):91. doi: 10.1186/s40478-025-02007-x. PMID: 40319321.))